Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 300

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 300
---
 fibrin sealant Kit (the “Tisseel”), from Teva, with Teva being Baxter’s exclusive                         
 distribution agent in Israel for Tisseel, for manufacture of GelrinC. The Supply Agreement was amended and restated. The Supply Agreement 
 provides for up to 1,000 kits of Tisseel of the 2 ml Tisseel kit, or 500 kits of Tisseel of the 4 ml Tisseel kit, or 200 kits of          
 Tisseel the 10 ml Tisseel kits per year at a fixed purchase price of $0.136 per unit. The payments under the Supply Agreement are         
 due 30 days from the date of invoice and the Company is subject to a service charge of 1% per month on all amounts past due.              |

The Supply Agreement had an initial
term of 3 years which ended on April 1, 2011; however, the Supply Agreement has an ever-green clause and is automatically renewable for
consecutive 1 year terms unless either party gives notice of termination at least 3 months prior to the then current term. The Supply
Agreement may be terminated without cause by Baxter upon 90 days’ prior written notice to the other parties. In addition, either
party may terminate the Supply Agreement in the event of an uncured material breach or insolvency.

| 4. | In January 2025, the                                                                                                              
 Company renewed its facility lease agreement until December 2025. The monthly rental obligations under non-cancellable leases are 
 approximately $5.5 (including $3 for administrative expenses).                                                                    |

As part of the agreement, the Company
has provided the landlord with a bank guarantee of approximately of $7 (NIS 27 thousand) which is valid until February 2026.

<div align='center'>F-45</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO THE UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 7:- | COMMITMENTS AND CONTINGENCIES (Cont.) |

Future minimum lease payments under
non-cancelable operating leases as of June 30, 2025 are as follows:

| 2025 |     | USD | 33 |
|:-----|:----|:----|---:|
|      |     | $   | 33 |

The Company has elected to utilize
the practical expedient in ASC